CNBC's "Fast Money" Biotech Breaks Out… And AI Impact On The Real Estate Industry 11/11/25
Nov 11, 2025
David Reisinger, a biopharma analyst and Senior Managing Director at Lyric Partners, discusses the current rally in the biotech sector, driven by M&A activity and valuation improvements. He highlights Bristol Myers as a misunderstood stock and the potential for large transactions in various therapeutic areas. In a surprising twist, AI's impact on real estate is explored, with Barry Sternlicht warning about job displacement while emphasizing efficiency gains. The conversation navigates the ripple effects of AI on the industry and its strategic implications.
AI Snips
Chapters
Transcript
Episode notes
Biotech Breakout Matches Big Tech
- Biotech and broader health care have rallied and are nearly neck-and-neck with mega-cap tech year-to-date.
- Valuations are discounted and M&A activity could push further gains into 2026.
Valuation Gap Fuels M&A Potential
- Large-cap pharma names are trading at low multiples while some growth winners like Eli Lilly trade rich.
- This valuation gap plus anticipated M&A make healthcare an attractive rotation target.
Invest By Risk‑Reward And Catalysts
- Focus investments where risk-reward and pipeline prospects look best across large and mid-cap biopharma.
- Watch for upcoming binary clinical readouts and M&A that can move shares quickly.